This most recent twist from the Lykos Therapeutics saga threatens A serious overhaul of the corporation’s tactic and course, with Musk ally and billionaire investor Antonio Gracias appearing to desire to just take the organization again towards its nonprofit drug advancement roots and a more Doblinite philosophy.The food allergy software was subm